(AMLX) Amylyx Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.510m USD | Total Return: 192.9% in 12m
Avg Turnover: 14.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 29.1% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
No distinct edge detected
Amylyx Pharmaceuticals, Inc. (AMLX) is a Cambridge-based clinical-stage biotechnology firm focused on developing therapies for neurodegenerative and endocrine disorders. The company’s pipeline is headlined by Avexitide, a GLP-1 receptor antagonist currently in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. Additionally, Amylyx is advancing AMX0035 for Wolfram syndrome and progressive supranuclear palsy, alongside early-stage candidates targeting amyotrophic lateral sclerosis (ALS).
The clinical-stage pharmaceutical sector is characterized by high research and development (R&D) costs and long regulatory lead times before reaching commercialization. Business models in this space rely heavily on intellectual property protection and the successful navigation of multi-phase clinical trials required for FDA approval. For a deeper look at these clinical milestones, investors may find ValueRays data useful.
- Phase 3 clinical trial results for Avexitide determine future commercial viability
- AMX0035 regulatory approval status for Wolfram syndrome and progressive supranuclear palsy
- R&D expenditure levels impact cash runway and potential capital raises
- Expansion into GLP-1 receptor antagonist market dictates long-term valuation growth
- Clinical data readouts for AMX0114 influence investor confidence in ALS pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA 53.22 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -120.4m > Net Income -150.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.6m) vs 12m ago 29.02% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 39.77%; Δ -39.77% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.92 (Total Current Assets 285.0m - Total Current Liabilities 16.0m) / Total Assets 293.6m |
| B: -2.70 (Retained Earnings -792.7m / Total Assets 293.6m) |
| C: -0.59 (EBIT TTM -150.8m / Avg Total Assets 256.6m) |
| D: -38.77 (Book Value of Equity -792.5m / Total Liabilities 20.4m) |
| Altman-Z'' = -47.44 = D |
As of May 30, 2026, the stock is trading at USD 14.35 with a total of 923,898 shares traded.
Over the past week, the price has changed by +3.02%,
over one month by -8.01%,
over three months by -5.41% and
over the past year by +192.86%.
Amylyx Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AMLX.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.4 | 63.1% |
P/E Forward = 2.7739
P/S = 0.6625
P/B = 5.5265
Revenue TTM = 0.0 USD
EBIT TTM = -150.8m USD
EBITDA TTM = -150.3m USD
Long Term Debt = 4.48m USD (estimated: total debt 5.63m - short term 1.16m)
Short Term Debt = 1.16m USD (from shortTermDebt, last quarter)
Debt = 5.63m USD (from shortLongTermDebtTotal, last quarter) (leases 5.63m already included)
Net Debt = -274.1m USD (calculated: Debt 5.63m - CCE 279.8m)
Enterprise Value = 1.24b USD (1.51b + Debt 5.63m - CCE 279.8m)
Interest Coverage Ratio = unknown (Ebit TTM -150.8m / Interest Expense TTM 0.0)
EV/FCF = -10.25x (Enterprise Value 1.24b / FCF TTM -120.5m)
FCF Yield = -9.75% (FCF TTM -120.5m / Enterprise Value 1.24b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 20.2m) / Revenue TTM)
Tobins Q-Ratio = 4.21 (Enterprise Value 1.24b / Total Assets 293.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.63m)
Taxrate = 21.0% (US default 21%)
NOPAT = -119.1m (EBIT -150.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.85 (Total Current Assets 285.0m / Total Current Liabilities 16.0m)
Debt / Equity = 0.02 (Debt 5.63m / totalStockholderEquity, last quarter 273.2m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -274.1m / EBITDA -150.3m)
Debt / FCF = 2.27 (negative FCF - burning cash) (Net Debt -274.1m / FCF TTM -120.5m)
Total Stockholder Equity = 269.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.49% (Net Income -150.1m / Total Assets 293.6m)
RoE = -14.13% (Net Income TTM -150.1m / Total Stockholder Equity 1.06b)
RoCE = -14.13% (EBIT -150.8m / Capital Employed (Equity 1.06b + L.T.Debt 4.48m))
RoIC = -42.72% (negative operating profit) (NOPAT -119.1m / Invested Capital 278.8m)
WACC = 9.07% (E(1.51b)/V(1.52b) * Re(9.10%) + D(5.63m)/V(1.52b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.00 | Cagr: 22.74%
[DCF] Fair Price = unknown (Cash Flow -120.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.12 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.35 | Chg30d=+0.83% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=+0.03% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.38 | Chg30d=-6.11% | Revisions=-9% | GrowthEPS=+9.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.27 | Chg30d=-3.33% | Revisions=-9% | GrowthEPS=+8.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -9%